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Abstract 
Background: Human papillomavirus (HPV) associated cancers are increasingly reported globally, including in sub‑
Saharan Africa (SSA). However, with the exception of cervical HPV infection, data from SSA on the epidemiology of 
oral and genital HPV infections are limited. This study assessed the prevalence and concordance of oro‑genital and 
anal HPV genotype specific infections among women in the general population.
Methods: We conducted a cross‑sectional study in sexually active women aged 18–45 years in Ibadan, Nigeria. After 
a face‑to‑face interview and clinical examination, oral, cervical, vulvar, and anal samples were collected from partici‑
pants and tested by the Anyplex II 28 HPV assay. Descriptive and multivariable analyses were used to report preva‑
lence and risk factors associated with HPV infections.
Results: The prevalence of any vulva, cervical, anal, and oral HPV infections was 68.0% (210/309), 59.7% (182/305), 
56.8% (172/303), and 16.1% (14/286), respectively. There was an inverse relationship between age‑group and HPV 
prevalence of HPV in all anatomic sites except for the oral HPV infections. HPV 35 was the most prevalent high‑risk 
HPV genotype in the vulva, cervix and oral cavity. Associated risk factors for HPV infection in each of the anatomic sites 
were reported. Overall, 10.0% (31/310) women had concordance of any HPV type in the four anatomic sites.
Conclusion: There was a high prevalence of oro‑genital and anal HPV infections among sexually active Nigerian 
women, with concordance of HPV types in the cervix, vulva, anus and oral cavity. We advocate large longitudinal stud‑
ies that will involve sampling of multiple anatomic sites and inclusion of other women in the community for better 
understanding of HPV epidemiology in this region.
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Background
Worldwide, human papillomavirus (HPV)-associ-
ated cancers are estimated to account for 4.5% of all 
cancers, with the highest burden occurring in the 
low-middle income countries (LMIC) [1, 2]. HPV per-
sistent infection is associated with anogenital warts 
and with over 95.0% of cervical cancer, 88.0% of anal 
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cancer, 70.0% of vaginal cancers, 43.0% of vulvar can-
cers and 25.6% of head and neck cancers [2]. The natu-
ral history of high-risk HPV (HR-HPV) infections as a 
causative agent of cervical cancer is well documented 
[3]. A similar epidemiology of HPV infections has 
been reported in HPV associated cancers of vulvar, 
vagina and anal cavity [4, 5]. However, little is known 
on the role of persistence of oral HPV infections in 
oropharyngeal carcinogenesis. There is evidence that 
the detection of HPV in a genital site might be a risk 
factor for HPV infection detection in other sites. A 
recent systematic review found that the risk of anal 
HPV infection among HIV negative women with cer-
vical premalignant lesion is 12 times higher compared 
to women with normal cervix [6]. The three HPV vac-
cines (Cervarix®, Gardasil® and Gardasil®9) are effec-
tive primary preventive strategy for HPV infection 
and associated benign and malignant morbidity [2, 7]. 
However, access to these vaccines are limited in LIMC, 
particularly, in Africa [2, 7].
Nigeria has one of the highest burdens of cervical 
cancer in sub-Saharan Africa after eastern and south-
ern Africa [2]. It is estimated that 14,943 new cervical 
cancer cases and 10,403 related deaths occur annually 
in Nigeria, accounting for 27.2% of cervical cases and 
20.0% of cervical cancer deaths in West Africa [2]. A 
study in Nigeria reported that the age-standardized 
incidence rates per annum for some HPV attribut-
able cancers among women are as follows: 28.3 per 
100,000 for cervical cancers, 0.6 per 100,000 for anal 
cancers, 0.5 per 10,000 for vulvar cancers and 0–0.3% 
per 100,000 for oropharyngeal cancers [8]. The most 
common of the 13 HR-HPV genotypes associated with 
cervical cancer in Nigeria are HPV-16, -18 and -35 
[9–12]. Although HPV vaccines have been licenced in 
Nigeria, the vaccine is only available on out-of-pocket 
purchase. In the last 20 years, the prevalence of cervi-
cal HPV infections ranged from 3.5% to 37.0% among 
the healthy population in the community, depend-
ing on the age, study population and associated co-
morbidities such as HIV infection [9, 11, 13, 14]. 
There are no published studies on the prevalence of 
oral, vulvar, and anal HPV infections among sexually 
active women in Nigeria and many countries in SSA. 
Therefore, it is important to understand the epidemi-
ology of HPV in other sites aside the cervix to be able 
to develop a robust policy and programme including 
HPV vaccination in the country. The aim of this study 
is to determine the prevalence of HPV and associated 
risk factors, and to compare the concordance of HPV 
infections in the four anatomical sites.
Methods
Study design, population and study site
This household survey was conducted among sexually 
active women aged 18–45  years, from the general pop-
ulation in two local government areas (LGA) in Ibadan. 
Two contiguous peri-urban communities were selected 
in Akinyele LGA: (Moniya [population: 53,000] and Sasa 
[population: 25,000]). Mokola [population: 77,000], a 
high-density urban community in Ibadan North LGA 
was the second study site. These study sites were selected 
because they are heterogenous in culture, religion and 
socio-economic/demographic profile. Each community 
is comprised of smaller enumeration areas (EA)—this is 
a small, compact area, carved out of a bigger locality or 
a group of localities with well-defined and identifiable 
boundaries. It usually has a unique name and code for 
identification. EAs represent the primary sampling unit 
during census.
The study excluded young adolescents (< 18  years), 
pregnant or nursing mothers, women not resident at the 
study sites and those that declined participation includ-
ing refusal for biological sample collection. Assuming an 
alpha of 0.05 and a design effect of 2 owing to the clus-
tered sampling design, a sample size of 300 was calcu-
lated to be able to estimate the prevalence of HPV and 
determine associated risk factors in each of the four ana-
tomic sites with adequate precision among women. The 
research assistants, nurses and laboratory staff had an 
intensive three-week training and participated in com-
munity engagement before the study commenced.
Study procedures
Sampling and enrolment of study participants
Eligible people were selected through a two-stage sam-
pling technique. The first stage sampling involved ran-
dom selection of four EAs each at Mokola and Moniya, 
and one EA at Sasa by probability proportional to size 
using the 2006 National Population Commission Census 
lists of the EAs [15]. Each house was assigned a unique 
identification number. House listing of women aged 
18–45 years were done by female research assistants. The 
house listing data from each of the study sites were strati-
fied into two age groups, young adults (18–24 years) and 
older adults (25–45 years), to serve as a sampling frame. 
The second stage sampling involved a systematic random 
sampling of eligible women from each sampling frame till 
the desired sample size of 310 was achieved.
Eligible participants were randomly enrolled at home 
by female research assistants who explained the study 
objectives and provided potential participants with an 
information leaflet in English or in a local language (Yor-
uba/Hausa/Igbo). Individuals that agreed to participate 
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were given appointment to be seen in a local primary 
healthcare centre. Potential participants had reminder 
phone calls at 72 h and 24 h before and a short message 
service on the morning of their clinic appointment.
Clinic visit, interview, sample collections and follow‑up
At the clinic, participants signed a written or witnessed 
informed consent following a repeat explanation of study 
procedures, including collection of biological samples. 
A face-to-face interview was conducted in English or in 
Yoruba for participants that could not understand Eng-
lish. The interview covered socio-demographics, sexual 
behaviours (e.g. vaginal, oral and anal sex) and hygiene 
practices, intravaginal practices, alcohol, smoking and 
stimulant use, previous STI and awareness about HPV 
vaccine. After the interview, a female nurse collected 
blood for a rapid diagnostic HIV test and other biologi-
cal samples. Samples from participants who did not wish 
to know their HIV were tested by an RDT in the labora-
tory. This HIV testing protocol was based on the National 
Guidelines for HIV Prevention Treatment and Care, Fed-
eral Ministry of Health, Nigeria [16]. HIV positive partic-
ipants were referred for management following national 
protocols.
Samples were also collected by a nurse from the mouth, 
cervix, vulvar and anal cavity in separate sample bottles. 
Briefly, an oral sample was collected using a 30  s oral 
rinse and gargle method with 10mls of Scope mouth wash 
(Procter & Gamble©). The nurse demonstrated the rinse 
and gargle procedure to a participant prior to sample col-
lection. The participant sample was then collected into a 
10 ml labelled sample bottle. and placed immediately into 
a cold box (2–4  °C). For the vulvar sample, the tip of a 
Dacron swab was used to rub the introitus on either side 
of the vaginal orifice without touching the urethral ori-
fice. The cervical sample was then collected by inserting a 
sterile Cusco speculum into the vagina to expose the cer-
vix. The tip of a new Dacron swab was inserted into the 
cervical os and gently rotated 360 degrees with care being 
taken to avoid trauma to the cervix and potential bleed-
ing before removing it. An anal sample was collected with 
the participant in a left lateral position. A Dacron swab 
was inserted into the anal canal (about 5–6  cm beyond 
the anal verge) and rotated 360 degrees with gentle pres-
sure around the anal verge before removal. Each of the 
samples collected with swabs were placed in separate 
2 ml cryotubes that were labelled with a barcoded sticker 
prior to being placed into a cold box (2–4  °C). All sam-
ples were subsequently stored in a − 80 °C freezer at the 
Institute of Advanced Medical Research and Training, 
College of Medicine, University of Ibadan, Nigeria until 
shipment to Catalan Institute of Oncology, Spain. Health 
related incentives (a bar of soap, toothbrush and paste), a 
soft drink and biscuit and 1000 Naira (2.8GBP) to cover 
transportation.
HPV DNA sample analysis
HPV genotyping of the samples was performed at the 
Catalan Institute of Oncology, Spain using the Anyplex™ 
II HPV28 assay (Seegene, Seoul, South Korea). This assay 
detects 28 HPV genotypes, including HR-HPV (HPV-16, 
-18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59 and -68), 
LR-HPV (HPV-6, -11, -40, -42, -43, -44, -53, -54 and -70) 
and possibly carcinogenic genotypes (HPV-26, -61, -66, 
-69, -73 and -82).
DNA extraction from the mouthwash was performed 
using the Maxwell® 16 LEV Blood DNA kit (Promega 
Corp., Madison, WI, USA). Briefly, mouthwash liquid 
samples were spin at 12.000xg for 20 min. After discard-
ing supernatant, cell pellet was eluted in 300ul of lysis 
buffer + 30ul Proteinase K and DNA extraction per-
formed following the manufacture’s instructions. DNA 
was extracted from cervical, vulvar and anal dry swabs 
using the Maxwell 16 Buccal swab LEV DNA Purifica-
tion kit (Promega Corp., Madison, WI, USA). Briefly, dry 
swabs were eluted in 300 ul of lysis buffer + 30 ul Protein-
ase K, incubated for 20  min. at 56  °C and spin at max. 
speed for 2  min. DNA extraction from eluted samples 
was performed following the manufacture’s instructions.
The Anyplex™ II HPV28 detection test was performed 
as recommended by the manufacturer. The data record-
ing and interpretation were automated with Seegene 
viewer software (Seegene, Seoul, South Korea).  Beta 
(β)-globin was used as the internal control to demon-
strate the presence of human DNA in each sample and 
to determine invalid samples. However, any sample that 
was positive for HPV but negative for Beta (β) globin was 
considered as valid.
Data management
Data were double entered into REDCap software (Van-
derbilt University, Nashville Tennessee, USA). Thereafter, 
the raw data were exported in CSV format and saved. The 
data were imported into STATA 16.0 (Stata 2019. Statisti-
cal Software: Release 16. College Station, TX: StataCorp 
LLC) software for analysis.
The participants’ selected descriptive variables were 
summarised using frequencies and proportions for the 
categorical variables and mean and standard devia-
tions for the continuous variable. The primary outcome 
was prevalence of any HPV infection. The prevalence of 
HR-HPV and LR-HPV infection and groups classified 
according to the 2009 IARC epidemiological oncogenic 
classification (Groups 1, 2a, 2b and 3) for each of the ana-
tomical sites were also calculated with their 95% confi-
dence intervals. The trends of association between each 
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classification of HPV infection and the age group of par-
ticipants were calculated with ANOVA.
A conceptual framework for the risk factor analysis of 
any HPV infection was developed (Additional file 1: Fig. 
S1). Associations with any HPV infection were explored 
to determine independent risk factors for infection. Any 
HPV infection was treated as a binary outcome; each 
anatomical site—oral, cervical, vulva and anal cavity—
was analysed separately. Logistic regression was applied 
to obtain crude estimates for the association between 
any HPV infection and potential risk factors. Adjusted 
estimates were obtained using a hierarchical modelling 
technique. Age group and study sites were included in 
the adjusted estimates a priori. Level 1 sociodemographic 
variables included ethnicity, religion, highest educational 
level, ever had Qur’anic education, current occupation, 
monthly income and current marital status. Each vari-
able was added one by one to the model that included 
age group and study site. P values were obtained by likeli-
hood ratio tests. Any variable that met a p value ≤ 0.10 
was included in the adjusted model. All level 1 variables 
were adjusted.
Level 2 behavioural variables included age at first vagi-
nal sex, age difference between first vaginal sex partner 
and the participant, lifetime number of vaginal sex part-
ners, ever cleansed vagina, condom use during last vagi-
nal sex, ever had oral sex (given or received), history of 
transactional sex, ever had mutual masturbation, history 
of female genital mutilation, alcohol use, illicit drug use, 
ever had STIs and ever heard of HPV. Each level 2 vari-
able was added one by one to a model that included level 
1 variables that met a p value cut off of ≤ 0.1 after adjust-
ing the ‘core variables’. Any level 2 variable that met a p 
value cut off of ≤ 0.1 was included with the level 1 core 
variables in the level 2 adjusted model. Level 3 biological 
variables were laboratory detection of concurrent HPV 
infection from the other three anatomical sites apart 
from the outcome measure. For example, if the outcome 
measure was to determine risk factor for any cervical 
HPV, concomitant detection in vulvar, anal and oral sites 
were included as explanatory variables. Each level 3 vari-
able was added one by one to a model that included level 
1 ‘core variables’ and level 2 factors that met a p value 
cut off of ≤ 0.1. Any level 3 variable that met a p value 
cut off of ≤ 0.1 was included with the level 1 and level 2 
‘core variables’ in the level 3 adjusted model. This strategy 
allowed the effects of variables at each level of the frame-
work to be assessed, adjusted for more distal variables.
The concordance of HPV between oral, cervical, vulvar 
and anal samples in individual participant was defined 
as the presence of the same type of virus across the four 
sites. The proportion of concordance for specific HPV 
type was calculated as the number of each HPV type in 
all the four sites, any of three and any of two anatomical 
sites.
Results
Out of the 930 eligible women listed, 304 in Mokola, 
Ibadan North LGA and 297 in Moniya/Sasa, Akinyele 
LGA were randomly selected and visited at home; only 
177 and 159 women in Mokola and Moniya/Sasa, respec-
tively, were met at home and invited to the clinic to par-
ticipate in the study. Of the 310 women that consented 
and participated, 157 and 153 women were from Mokola 
and Moniya/Sasa, respectively. The enrolment of partici-
pants at the two study sites was summarised in Fig. 1.
Participant characteristics
The overall mean age of participants was 29  years 
(SD = 7) (Table  1). There was a higher proportion of 
women aged 25–34 and 35–45 years in Moniya/Sasa than 
in Mokola (p = 0.04). There were significant differences 
between women in Mokola and Moniya/Sasa for other 
sociodemographic factors such as ethnicity, religion, 
current marital status and personal ownership of items 
such as a television, a radio and a generator (p < 0.001). 
Overall, 39% were aged between 18–24  years and 77% 
were from Yoruba speaking ethnic group, 54% were Mus-
lim and 57% had reached secondary education or above. 
Most women were semi-skilled (70%) and 11% had no 
monthly income.
Among the selected behavioural factors (Table 1), par-
ticipants in Mokola and Moniya/Sasa were significantly 
different in the number of mean lifetime partners for 
vaginal sex (p < 0.001); history of ever cleansed vaginal 
sex (p < 0.001); reported condom use during last vagi-
nal sex (p = 0.004), history of ever giving (p = 0.009) or 
receiving oral sex (p = 0.006), history of mutual mastur-
bation (p < 0.001), female genital mutilation (p = 0.006), 
ever drank alcohol (p < 0.001) and previous history of 
STI (p = 0.041). In total, a quarter of women had vaginal 
sex debut by 17 years and half of these women (51%) had 
an age difference of up to 5 years with their first vaginal 
sex partner. Most women had ever cleansed their vagina 
(88%) and reported not using condom during their last 
vaginal sex (82%). Only 11% had ever gave oral sex while 
12% had ever received oral sex from a male partner. Three 
quarter reported ever engaging in mutual masturba-
tion with sexual partners (75%), a little over half had had 
female genital mutilation (54%) and 27% had ever drank 
alcohol. Only few women reported a history of transac-
tional sex (6%), use of illicit drugs (1%) and 7% had ever 
heard of HPV. Previous STI was reported by 14% par-
ticipants. Eight participants (six in Mokola and two in 
Moniya) tested positive to HIV infection while only one 
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participant in Mokola reported ever having heterosexual 
anal sex (data not shown).
The two biological factors that differed among women 
in the two communities were proportion of women with 
any anal HPV (p = 0.010) and oral HPV (p = 0.004). Over-
all, the proportion of women with any HPV was highest 
in the vulvar followed by cervical, anal and oral sites.
Prevalence of cervical, vulvar, anal and oral HPV Infection
Three hundred and ten samples were collected from each 
of the anatomical sites. of these, twenty-four (7.7%) oral 
samples, seven (2.2%) anal samples, five (1.6%) cervical 
samples and one (0.3%) vulvar sample were considered 
invalid due to the low amount of β globin portion of the 
DNA. All invalid samples were treated as missing.
Overall, the prevalence of any HPV infection in 
women was 68.0% (95% CI 62.4–73.1) in the vulvar 
samples, 59.7% (95% CI 53.–65.2) in the cervical sam-
ples, 56.8% (95% CI 51.0–62.4) in the anal samples and 
16.1% (95% CI 12.0–12.9) in the oral samples (Table 2). 
Generally, the prevalence of any HPV was highest in 
each of the four anatomical sites among participants 
aged 18–24  years, and it decreased with increasing 
age of the participants. There was a significant inverse 
relationship between the age group of the partici-






304 were randomly 
selected and 
visited at home
297 were randomly 
selected and 
visited at home
177 (58%) enrolled 
and invited to the 
clinic to parcipate
159 (54%) enrolled 
and invited to the 
clinic to parcipate
127 (42%) were not 
found at home aer 3 
visits 
138 (46%) were not 
found at home aer 
3 visits 
157 (89%) 
parcipated in the 
study
153 (96%) 
parcipated in the 
study
7 (4%) refused 
parcipaon
13 (7%) ineligible 
parcipants
2 (1%) refused 
parcipaon
4 (3%) ineligible 
parcipants
930 Females
Fig. 1 Participants’ enrolment flow for the household survey
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Table 1 Socio‑demographic characteristics of sexually active females in two communities in Ibadan, Nigeria
Variable Total N = 310 Mokola N = 157 Moniya/Sasa N = 153 p value
N (% column) N (%column) n (% column)
Socio-demographic factors (level 1)
Age, years
 Mean (SD) 29 (7) 28 (7) 29 (8) 0.481
Age group, years
 18–24 121 (39%) 61 (39%) 60 (39%)
 25–34 101 (33%) 60 (38%) 41 (27%) 0.040
 35–45 67 (28%) 36 (23%) 52 (33%)
Ethnicity
 Yoruba 240 (77%) 95 (61%) 145 (95%)
 Hausa/Fulani 37 (12%) 33 (21%) 4 (2%)
 Igbo 19 (6%) 16 (10%) 3 (2%)  < 0.001
 Others ethnic minorities 13 (4%) 13 (8%) 1 (1%)
Religion
 Christianity 140 (45%) 91 (58%) 49 (32%)
 Islam 168 (54%) 64 (41%) 104 (68%)  < 0.001
 Traditional 2 (1%) 2 (1%) 0 (0%)
Highest education level
 No formal education 6 (2%) 2 (1%) 4 (3%)
 Primary 56 (18%) 26 (16%) 30 (20%) 0.403
 Secondary 176 (57%) 87 (55%) 89 (58%)
 Tertiary 72 (23%) 42 (27%) 30 (20%)
Quranic education
 No 197 (64%) 98 (62%) 99 (65%) 0.676
 Yes 113 (36%) 59 (38%) 54 (35%)
Occupation
 No current paid job (e.g. student, housewife) 54 (17%) 36 (23%) 18 (12%)
 Unskilled worker (e.g. office assistant) 18 (6%) 9 (6%) 9 (6%) 0.066
 Semi‑skilled worker (e.g. driver, tailor) 218 (70%) 104 (66%) 114 (75%)
 Skilled worker (e.g. teacher, technician, doctor) 20 (7%) 8 (5%) 12 (8%)
Income per month
 No income 35 (11%) 17 (11%) 18 (12%)
 1–10,000 N (1–28USD) 126 (41%) 106 (67%) 105 (68%) 0.951
 10,001–20,000 N (> 28–56USD) 85 (27%) 26 (17%) 24 (16%)
  > 20,000 N (> 56USD) 64 (21%) 8 (5%) 6 (4%)
Current marital status
 Single and Living alone 82 (27%) 59 (38%) 23 (15%)
 Married and living as married 212 (68%) 89 (57%) 123 (80%)
 Divorced/widowed/separated and living alone 16 (5%) 9 (6%) 7 (5%)  < 0.001
Items personally owned by participant
 Mobile phone 265 (85%) 124 (79%) 141 (92%) 0.001
 Television 161 (62% 39 (25%) 122 (80%)  < 0.001
 Radio 124 (40%) 26 (17%) 98 (64%)  < 0.001
 Generator 77 (25%) 16 (10%) 61 (40%)  < 0.001
 House 14 (5%) 1 (1%) 13 (9%) 0.001
Behavioural factors (Level 2)
Age at first vaginal  sex1, years
 ≤ 18 133 (44%) 73 (48%) 60 (39%)
 19–21 106 (35%) 47 (31%) 59 (39%) 0.324
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Table 1 (continued)
Variable Total N = 310 Mokola N = 157 Moniya/Sasa N = 153 p value
N (% column) N (%column) n (% column)
 22–24 39 (13%) 21 (14%) 18 (12%)
 ≥ 25 26 (9%) 11 (7%) 15 (10%)
Age of first vaginal sex  partner2, years
 Mean (SD) = 274 19 (3) 19 (3) 20 (3) 0.779
Age difference between first vaginal sex partner and 
participant,  years3
0.808
 ≤ 5 139 (51%) 69 (50%) 70 (51%)
  ≥ 6 135 (49%) 69 (50%) 66 (49%)
Number of lifetime partners for vaginal sex  < 0.001
 Number of vaginal sex partners (mean (SD)) 1.90 (1.41) 2.21 (1.75) 1.59 (0.82)
Number of lifetime partners for vaginal sex
 Single vaginal partner 163 (53%) 73 (47%) 90 (59%) 0.030
 Multiple vaginal sex partners (≥ 2) 147 (47%) 84 (53%) 63 (41%)
Ever cleansed inside  vagina4
 No 36 (12%) 33 (21%) 3 (2%)  < 0.001
 Yes 274 (88%) 124 (79%) 150 (98%)
Condom use during last vaginal sex
 No 254 (82%) 119 (76%) 135 (88%) 0.004
 Yes 56 (18%) 38 (24%) 18 (12%)
Ever gave oral sex to a male partner
 No 275 (89%) 132 (84%) 143 (93%) 0.009
  Yes 35 (11%) 25 (16%) 10 (7%)
Ever received oral sex from a male partner 274 (88%) 131 (83%) 143 (93%)
 No 36 (12%) 26 (17%) 10 (7%) 0.006
 Yes
Ever had transactional sex
 No 291 (94%) 145 (92%) 146 (95%) 0.260
 Yes 19 (6%) 12 (8%) 7 (5%)
Ever had mutual  masturbation5
 No 76 (25%) 20 (13%) 56 (37%)  < 0.001
 Yes 234 (75%) 137 (87%) 97 (63%)
Female genital  mutilation6
 No 144 (46%) 85 (54%) 59 (39%) 0.006
 Yes 166 (54%) 72 (46%) 94 (61%)
Ever drank alcohol
 No 226 (73%) 90 (57%) 136 (89%)  < 0.001
 Yes 84 (27%) 67 (43%) 17 (11%)
Ever taken any illicit  drugs7
 No 307 (99%) 154 (98%) 153 (100%) 0.2484
 Yes 3 (1%) 3 (2%) 0 (0%)
Ever had an STI
 No 267 (86%) 129 (82%) 138 (90%) 0.041
 Yes 43 (14%) 28 (18%) 15 (10%)
Ever heard of HPV
 No 287 (93%) 149 (95%) 138 (90%) 0.114
 Yes 23 (7%) 8 (5%) 15 (10%)
Biological factors (Level 3)
Cervical HPV  infection8 0.413
 No 123 (40%) 59 (38%) 64 (43%)
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LR-HPV, as well as multiple HPV infections (two or 
more different genotypes of HPV from a sample) in 
cervical samples. However, in the vulvar samples, a 
significant inverse relationship was found between 
the age group of participants and any class 1, any LR-
HPV and multiple HPV infections. Similarly, there 
was also a significant inverse relationship between age 
group and the prevalence of any LR-HPV and multiple 
HPV infections in anal samples. The prevalence of any 
oral HPV was highest among the youngest age group 
(18–24 years), but this association was not statistically 
significant.
The prevalence of any HPV infection according 
to the IARC classifications was highest in the vul-
var samples compared to the other three anatomical 
sites (Table 2). Similarly, the highest prevalence of any 
HR-HPV, LR-HPV and multiple HPV genotypes was 
also recorded in the vulvar samples compared to the 
other three anatomical sites. The two most prevalent 
HR-HPV genotypes by anatomical site were HPV-
35 (8.5%) and HPV-39 (7.2%) in the cervical samples; 
HPV-35 (8.7%) and HPV-52 (8.1%) in the vulvar sam-
ples; HPV-52 (8.9%) and HPV-45 (7.3%) in the anal 
samples; and HPV-51 (3.2%) and HPV-18/35/39 (1.4%) 
in the oral samples (Fig. 2). HPV-42 was the common-
est LR-HPV specific genotype detected in the anal 
(13.2%), vulvar (12.6%), cervical (11.2%) and oral sam-
ples (3.8%). HPV-6 was the second most prevalent LR 
type in the cervical (6.2%), anal (8.9%), and oral (3.2) 
samples, while HPV-66 and HPV-54 were the second 
most detected LR genotypes in the vulvar (10.7%) and 
cervical (6.2%) samples, respectively (Fig. 2; Additional 
file 1: Fig. S2).
Risk factors associated with cervical, vulvar, anal and oral 
HPV Infection
Tables  3 and 4 showed results of crude and adjusted 
models for the risk factor analyses for the four anatomic 
sites.
In the adjusted analysis, age-group, the number of 
lifetime vaginal sex partners and detection of concomi-
tant vulvar, anal and oral HPV infection remained asso-
ciated with odds of cervical HPV infection. Women 
aged 26–34  years and 35–45  years had 0.81 (95% CI 
0.46–1.41) and 0.44 (95% CI 0.25–0.78) odds of having 
cervical HPV infection, respectively, compared to those 
aged 18–24  years. There was 1.54 (95%CI 1.16–2.04) 
higher odds of having cervical HPV infection for a unit 
increase in the number of lifetime partner for vaginal 
sex. The odds of detecting cervical HPV infections was 
12.85 times (95%CI 5.70–28.99), 4.37 times (95%CI 1.50–
12.71) and 3.48 times (95%CI 1.74–6.96) in women that 
had concomitant vulvar, oral and anal HPV infections, 
respectively, compared to those with no HPV infections 
at these anatomical sites (Table 4).
Independent risk factors associated with any vulvar 
HPV infection included: current marital status; age dif-
ference between the first vaginal sex partner and the 
participant; number of lifetime partners for vaginal sex 
partners; detection of concomitant cervical and anal 
HPV infection. There were lower odds (aOR = 0.49, 95% 
CI 0.25–0.99) of vulvar HPV infection among married 
or living as married women relative to single women. 
Table 1 (continued)
Variable Total N = 310 Mokola N = 157 Moniya/Sasa N = 153 p value
N (% column) N (%column) n (% column)
 Yes 182 (60%) 96 (62%) 86 (57%)
Vulvar HPV infection 0.941
No 99 (32%) 50 (32%) 49 (32%)
Yes 210 (68%) 107 (68%) 103 (68%)
Anal HPV  infection9 0.010
 No 131 (43%) 55 (36%) 76 (51%)
 Yes 172 (57%) 98 (64%) 74 (49%)
Oral HPV  infection10 0.004
 No 240 (84%) 111 (78%) 129 (90%)
 Yes 46 (16%) 32 (22%) 14 (10%)
1 6 missing; 236 missing; 3 N = 269—36 participants did not provide information to calculate the age difference between first vaginal sex partner and participant; 
4Cleansing of vagina was defined as using water or another substance to clean inside vagina by inserting half or whole finger; 5Mutual masturbation question was 
‘have you or your partner ever touched each other’s genital area by hand? (Yes or No); 6Female genital mutilation was based on the clinical examination of the female 
external genitalia for evidence of genital circumcision by the research nurse at the clinic (Yes or No); 7Illicit drugs are banned substances or drugs taken by participants 
for non‑medical reasons in Nigeria; 8 N = 305—four participants did not have cervical HPV results; 9 N = 298‑seven participants did not have anal HPV results; 
10 N = 281–24 participants did not have oral HPV results
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Table 2 Prevalence of Cervical, Vulvar, Anal and Oral Human papillomavirus infections among sexually active women from the general 
population in two communities in Ibadan, Nigeria (N = 310)
Variable Cervical sample Vulvar sample Anal sample Oral sample
n/N1 Prevalence % [95% 
CI]
n/N Prevalence (%) [95% 
CI]
n/N Prevalence (%) [95% 
CI]
n/N Prevalence (%) 
[95% CI]
Any HPV genotype p = 0.014* p = 0.523 p = 0.021* p = 0.669
 18–24 years 79/118 66.9 (57.8–75.3) 86/121 71.1 (62.1–79.0) 74/120 61.7 (52.4–70.4) 20/111 18.0 (11.4–26.4)
 25–34 years 62/100 62.0 (51.7–71.5) 68/100 68.0 (57.9–77.0) 57/97 58.9 (48.3–68.7) 15/92 16.3 (9.4–25.5)
 35–45 years 41/87 47.1 (36.3–58.1) 56/88 63.6 (52.7–73.6) 41/86 47.7 (36.8–58.7) 11/83 13.3 (6.8–22.5)
 Overall 182/305 59.7 (53.9–65.2) 210/309 68.0 (62.4–73.1) 172/303 56.8 (51.0–62.4) 46/286 16.1 (12.0–20.9)
HPV classification by 
IARC 2 Class 1—Carci-
nogenic3
p = 0.074* p = 0.026* p = 0.230* p = 0.967
 18–24 years 58/118 49.2 (39.8–58.5) 65/121 53.7 (44.4–62.8) 50/120 41.7 (32.7–51.0) 11/111 9.9 (5.1–17.0)
 25–34 years 41/100 41.0 (31.3–51.3) 48/100 48.0 (37.9–58.2) 38/97 39.2 (29.4–49.6) 9/92 9.9 (4.6–17.8)
 35–45 years 29/87 33.3 (23.6–44.3) 36/88 40.9 (30.5–51.9) 26/86 30.2 (20.8–41.1) 9/83 10.8 (5.1–19.6)
 Overall 128/305 42.0 (36.4–47.7) 149/309 48.2 (42.5–53.9) 114/303 37.6 (32.1–43.3) 29/286 10.1 (6.9–14.2)
Class 2A—Probable 
carcinogenic4
p = 0.8355 p = 0.954 p = 0.094b p = 0.749b
 18–24 years 5/118 4.2 (1.4–9.6) 9/121 7.4 (3.5–13.7) 8/120 6.7 (2.9–12.7) 1/111 0.9 (0.02–4.9)
 25–34 years 4/100 4.0 (1.1–9.9) 8/100 8.0 (3.5–15.2) 1/97 1.0 (0.0–5.6) 0/92 0
 35–45 years 5/87 5.7 (1.9–12.9) 6/88 6.8 (2.5–14.3) 5/86 5.8 (1.9–13.0) 1/83 1.2 (0.03–6.5)
 Overall 14/305 4.6 (2.5–7.6) 23/309 7.4 (4.8–11.0) 14/303 4.6 (2.5–7.6) 2/286 0.7 (0.08–2.5)
Class 2B—Possible 
carcinogenic6
p = 0.006* p = 0.102 p = 0.265 p = 0.966
 18–24 years 54/118 45.8 (36.6–55.2) 60/121 49.6 (40.4–58.8) 47/120 39.2 (30.4–48.5) 7/111 6.3 (2.6–12.6)
 25–34 years 40/100 40.0 (30.3–50.3) 50/100 50.0 (39.8–60.2) 40/97 41.2 (31.3–51.7) 6/92 6.5 (2.4–13.7)
 35–45 years 21/87 24.1 (15.6–34.5) 32/88 36.4 (26.4–47.3) 26/86 30.2 (20.8–41.1) 6/83 7.2 (2.7–15.1)
 Overall 115/305 37.7 (32.2–43.4) 142/309 46.0 (40.3–51.7) 113/303 37.3 (31.8–43.0) 19/286 6.6 (4.0–10.2)
Class 3—Unclassified7 p = 0.019* p = 0.154 p = 0.597 p = 0.835
 18–24 years 14/118 11.9 (6.6–19.1) 16/121 13.2 (7.8–20.6) 12/120 10.0 (5.3–16.8) 4/111 3.6 (0.9–9.0)
 25–34 years 5/100 5.0 (1.6–11.3) 8/100 8.0 (3.5–15.2) 6/97 6.2 (2.3–13.0) 2/92 2.2 (0.3–7.6)
 35–45 years 2/87 2.3 (0.3–8.1) 5/88 5.7 (1.9–12.8) 7/86 8.1 (3.3–16.1) 3/83 3.6 (0.8–10.2)
 Overall 21/305 6.9 (4.3–10.3) 29/309 9.4 (6.4–13.2) 25/303 8.3 (5.4–11.9) 9/286 3.1 (1.4–5.9)
Any HR‑HPV 
 genotypes8
p = 0.095* p = 0.142* p = 0.243 p = 0.965
 18–24 years 60/118 53.1 (44.7–61.3) 69/121 59.3 (51.0–67.3) 53/120 44.2 (35.1–53.5) 12/111 10.8 (5.7–18.1)
 25–34 years 44/100 38.0 (28.1–48.8) 51/100 44.6 (34.2–55.3) 38/97 39.2 (29.4–49.6) 9/92 9.8 (4.6–17.8)
 36–45 years 31/87 33.3 (22.2–46.0) 38/67 41.8 (29.8–54.5) 28/86 32.6 (22.8–43.5) 9/83 10.8 (5.1–19.6)
 Overall 135/305 44.3 (38.6–50.0) 158/309 51.1 (45.4–56.8) 119/303 39.3 (33.7–45.0) 30/286 10.5 (7.2–14.6)
Any LR‑HPV 
 genotype9
p = 0.001* p = 0.047* p = 0.495 p = 0.891
 18–24 years 60/118 50.8 (41.5–60.2) 66/121 54.5 (45.2–63.6) 56/120 46.7 (37.5–56.0) 11/111 9.9 (5.1–17.0)
 25–34 years 41/100 41.0 (31.3–51.3) 50/100 50.0 (39.8–60.2) 44/97 45.4 (35.2–55.8) 8/92 8.7 (3.8–16.4)
 35–45 years 22/87 25.3 (16.6–35.7) 33/88 37.5 (27.4–48.5) 33/86 38.4 (28.1–49.5) 9/83 10.8 (5.1–19.6)
 Overall 123/305 40.3 (34.8–46.1) 149/309 48.2 (42.5–53.9) 133/303 43.9 (38.2–49.7) 28/286 9.8 (6.6–13.8)
Multiple HPV geno‑
types  infection10
p < 0.001* p = 0.012* p = 0.014* p = 0.7215
 18–24 years 54/118 45.8 (36.6–55.2) 59/121 48.7 (39.6–58.0) 51/120 42.5 (33.5–51.9) 4/111 3.6 (1.0–9.0)
 25–34 years 29/100 29.0 (20.4–38.9) 42/100 42.0 (32.2–52.3) 31/97 32.0 (22.9–42.2) 4/92 4.3 (1.2–10.8)
 35–45 years 18/87 20.7 (12.7–30.7) 25/88 28.4 (19.3–39.0) 20/86 23.3 (14.8–33.6) 5/83 6.0 (2.0–13.5)
 Overall 101/305 33.1 (27.9–38.7) 126/309 40.8 (35.2–46.5) 102/303 33.7 (28.4–39.3) 13/286 4.5 (2.4–7.6)
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Having 6 or more than lifetime vaginal sex partners 
was associated with a lower odds (aOR = 0.51, 95% CI 
0.29–0.90) of vulva HPV infection compared to those 
with smaller age difference. There were 2.03 (95% CI 
1.38–3.01) odds of HPV infection for each unit increase 
in the number of lifetime partner for vaginal sex. Con-
comitant cervical (aOR = 22.19, 95%CI 7.85–62.72) and 
anal (aOR = 6.68, 95% CI 2.44–18.26) HPV infections 
were associated with a higher odds of vulvar HPV infec-
tion compared to those with no concomitant infections 
at such anatomical sites (Table 4).
Only the age difference between the first vaginal sex 
partners and participants, number of lifetime partners 
for vaginal sex and the presence of concomitant HPV 
infection in the cervix and vulvar were found to be inde-
pendently associated with the risk of detecting anal HPV 
infection. There were lower odds (aOR = 0.58, 95% CI 
0.34–1.00) of having anal HPV infection among women 
whose age difference with her first vaginal sex partner 
was six years or more compared to those with smaller 
age differences. The odds of anal HPV infections were 
1.92 (95% CI 1.35–2.71) higher for each unit increase in 
number of lifetime partner for vaginal sex. The odds of 
having anal HPV was higher in women with concomi-
tant cervical (aOR = 4.10, 95% CI 1.85–9.11) and vulvar 
(aOR = 5.47, 95% CI 2.11–14.20) HPV infection com-
pared with those without HPV infections at these ana-
tomical sites (Table 4).
The factors that were associated with risk of oral HPV 
infections include age group and concomitant cervi-
cal HPV infection. There were lower odds of having oral 
HPV infection in women in Moniya/Sasa (aOR = 0.38, 
95% CI 0.19–0.74) compared to those in Mokola. The 
odds of having oral HPV infection was 4.81 (95%CI 1.58–
14.62) higher in women with concomitant cervical HPV 
infection than those with no such infection (Table 4).
Concordance of genotype specific HPV infection
Thirty-one (10.0%) out of 310 women had concordance 
of any HPV infection in the four anatomical sites of the 
Table 2 (continued)
1 n/N—number of samples with positive HPV infection as numerator and total samples with valid result as denominator; 2IARC—International Agency for Research 
on Cancer (*HPV genotypes in IARC classification that are not included in the Anyplex II HPV28 platform); 3Class 1 IARC HPV‑16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59; 
4Class 2A IARC HPV—68; 5Bartlett’s test for equal variances were significant (p < 0.05); 6Class 2B IARC HPV—5*, 8*, 26, 30*, 34*, 40, 42, 43, 44, 53, 54, 55*, 61, 66, 67*, 69, 
70, 71*, 72*, 73, 81*, 82, 83*, 84*, 85*, 97*, IS39* and CP6108*; 7Class 3 IARC HPV—6, 11; 8HR‑HPV Group—Class 1 IARC HPV and Class 2A IARC HPV; 9LR‑HPV—Class 
2b IARC and Class 3 IARC; 10Multiple HPV infection‑detection of two or more genotypes of HPV by Anyplex II HPV28 from a sample. All invalid samples were excluded 




















cervix vulva anal cavity oral cavity
Fig. 2 Prevalence of specific HPV genotypes according to the four anatomical sites
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Table 3 Descriptive summaries and unadjusted factors associated with cervical, vulvar, anal and oral human papillomavirus infection 
among sexually active women from the general population in two communities in Ibadan, Nigeria
Variable Cervical Vulvar Anal Oral
n/N (row, %) P  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 Crude 
OR (95%CI)
Socio-demographic factors
Study site p = 0.413 p = 0.942 p = 0.010 p = 0.003
 Mokola 96/155 (62%) 1 107/157 (68%) 1 98/153 (64%) 1 32/143 (23%) 1
 Moniya/Sasa 86/150 (57%) 0.83 
(0.52–1.31)
103/152 (68%) 0.98 (0.61–
1.58)
74/150 (49%) 0.55 (0.35–
0.87)
14/143 (10%) 0.38 (0.19–
0.74)
Age group, years p = 0.015 p = 0.525 p = 0.122 p = 0.664
 18–24 79/118 (67%) 1 86/121 (71%) 1 74/120 (62%) 1 20/111 (18%) 1
 25–34 62/100 (58%) 0.81 (0.46–
1.41)
68/100 (68%) 0.86 (0.49–
1.54)
57/97 (59%) 0.89 (0.51–
1.53)
15/92 (16%) 0.89 (0.43–1.85)
 35–45 41/87 (47%) 0.44 (0.25–
0.78)
56/88 (61%) 0.71 (0.40–
1.28)
41/86 (48%) 0.57 (0.32–
0.99)
11/83 (13%) 0.70 (0.31–1.54)
Ethnicity p = 0.175 p = 0.676 p = 0.612 p = 0.786
 Yoruba 136/236 (58%) 1 161/239 (67%) 1 131/234 (56%) 1 35/222 (16%) 1
  Others2 46/69 (67%) 1.47 
(0.84–2.58)
49/70 (70%) 1.13 (0.63–
2.02)
41/69 (59%) 1.15 (0.67–
1.99)
11/64 (17%) 1.11 (0.53–2.33)
Religion p = 0.840 p = 0.541 p = 0.451 p = 0.678
 Christianity/tra‑
ditional
85/141 (60%) 1 99/142 (70%) 1 81/137 (59%) 1 23/135 (17%) 1
 Islam 97/164 (59%) 0.95 
(0.60–1.51)
111/167 (66%) 0.86 (0.53–
1.39)
91/166 (55%) 0.84 (0.53–
1.33)
23/151 (15%) 0.88 (0.47–1.64)
Highest educa‑
tion level
p = 0.104 p = 0.749 p = 0.269 p = 0.866
 None/primary 32/62 (52%) 1 41/62 (66%) 1 29/61 (48%) 1 8/57 (14%) 1
 Secondary 111/171 (65%) 1.73 
(0.96–3.13)
122/175 (70%) 1.18 (0.64–
2.18)
101/171 (59%) 1.59 (0.88–
2.87)
28/165 (17%) 1.25 (0.53–2.93)
 Tertiary 39/72 (54%) 1.11 
(0.56–2.19)
47/72 (65%) 0.96 (0.47–
1.97)
42/71 (59%) 1.60 (0.80–
3.19)
10/64 (16%) 1.13 (0.41–3.10)
Quranic educa‑
tion
p = 0.954 p = 0.840 p = 0.998 p = 0.842
 No 116/194 (60%) 1 134/196 (68%) 1 109/192 (57%) 1 29/184 (16%) 1
 Yes 66/111 (59%) 0.99 
(0.61–1.59)
76/113 (67%) 0.95 (0.58–
1.56)
63/111 (57%) 1.00 (0.62–
1.60)
17/102 (17%) 1.07 (0.56–2.06)
Occupation p = 0.409 p = 0.791 p = 0.121 p = 0.935
 No current paid 
 job3
33/52 (63%) 1 39/54 (72%) 1 37/54 (69%) 1 9/50 (18%) 1
 Unskilled worker 9/18 (50%) 0.58 
(0.19–1.70)
12/18 (67%) 0.77 (0.24–
2.42)
11/18 (61%) 0.72 (0.24–
2.19)
3/17 (18%) 0.98 (0.23–4.12)
 Semi‑skilled 
worker
131/215 (61%) 0.90 
(0.48–1.68)
147/217 (68%) 0.81 (0.42–
1.56)
116/211 (55%) 0.56 (0.30–
1.06)
32/202 (16%) 0.86 (0.38–1.94)
 Skilled worker 9/20 (45%) 0.47 
(0.17–1.34)
12/20 (60%) 0.58 (0.20–
1.69)
8/20 (40%) 0.31 (0.11–
0.89)
2/17 (12%) 0.61 (0.12–3.14)
Income per 
 month4
p = 0.407 p = 0.207 p = 0.070 p = 0.556
 No income 19/33 (58%) 1 24/35 (69%) 1 23/35 (66%) 1 6/34 (18%) 1
 1–10,000 N 
(1–28USD)
124/209 (59%) 1.07 
(0.51–2.26)
79/125 (65%) 0.79 (0.35–
1.75)
67/122 (55%) 0.64 (0.29–
1.39)
16/112 (14%) 0.78 (0.28–2.18)
 10,001–20,000 N 
(> 28–56USD)
33/49 (67%) 1.52 
(0.61–3.79)
57/85 (86%) 0.93 (0.40–
2.17)
39/82 (48%) 0.47 (0.21–
1.08)
16/77 (21%) 1.22 (0.43–3.46)
  > 20,000 N 
(> 56USD)
6/24 (43%) 0.55 
(0.16–1.96)
50/64 (50%) 1.64 (0.65–
4.14)
43/64 (67%) 1.07 (0.45–
2.55)
8/63 (13%) 0.68 (0.21–2.15)
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Table 3 (continued)
Variable Cervical Vulvar Anal Oral
n/N (row, %) P  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 
Crude OR 
(95%CI)




p = 0.107 p = 0.040 p < 0.001 p = 0.323
 Single 54/79 (68%) 1 63/82 (77%) 1 61/82 (74%) 1 14/75 (19%) 1
 Married 117/210 (56%) 0.58 
(0.34–1.01)
134/211 (64%) 0.52 (0.29–
0.94)
104/206 (50%) 0.35 (0.20–
0.62)




11/16 (69%) 1.02 
(0.32–3.24)
13 (81%) 1.31 (0.34–
5.07)
7/15 (47%) 0.30 (0.10–
0.93)
4/14 (29%) 1.74 (0.48–6.38)
Behavioural factors
Age at first vagi‑
nal  sex6, years
p = 0.642 p = 0.612 p = 0.255 p = 0.082
  ≤ 15 20/32 (63%) 1 25/33 (76%) 1 23/33 (70%) 1 3/31 (20%) 1
 16–17 26/42 (62%) 0.98 
(0.38–2.52)
28/42 (67%) 0.64 (0.23–
1.78)
22/42 (52%) 0.48 (0.18–
1.25)
11/39 (15%) 3.67 (0.92–
14.57)
  ≥ 18 133/225 (59%) 0.87 
(0.40–1.86)
154/228 (68%) 0.67 (0.29–
1.55)
124/222 (56%) 0.55 (0.25–
1.21)






p = 0.232 p = 0.002 p = 0.005 p = 0.617
  ≤ 5 87/137 (64%) 1 106/139 (76%) 1 91/138 (66%) 1 24/134 (18%) 1
  ≥ 6 71/132 (54%) 0.67 
(0.41–1.09)
79/134 (59%) 0.45 (0.27–
0.75)
63/129 (46%) 0.49 (0.30–
0.81)
19/122 (16%) 0.85 (0.44–1.63)
Number of vagi‑
nal sex partners
p = 0.001 p < 0.001 p < 0.001 p = 0.198
 (Mean (SD)) 1.91 (1.41) 1.46 (1.16–
1.84)
1.91 (1.41) 1.59 (1.21–
2.07)
1.89 (1.40) 1.50 (1.19–
1.90)
1.89 (1.43) 1.14 (0.94–1.38)
Ever cleansed 
inside vagina
p = 0.294 p = 0.097 p = 0.876 p = 0.125
 No 18/35 (51%) 1 20/36 (56%) 1 20/36 (56%) 1 34/235 (14%) 1
 Yes 164/270 (61%) 1.46 
(0.72–2.96)
190/273 (70%) 1.83 (0.90–
3.71)
152/267 (57%) 1.06 (0.52–
2.13)
12/51 (24%) 1.82 (0.87–3.82)
Condom use at 
last vaginal sex
p = 0.719 p = 0.204 p = 0.508 p = 0.685
 No 148/250 (59%) 1 168/253 (66%) 1 138/247 (56%) 1 38/242 (16%) 1
 Yes 34/55 (62%) 1.12 
(0.61–2.03)
42/56 (75%) 1.52 (0.79–
2.93)
34/56 (61%) 1.22 (0.68–
2.21)
8/44 (18%) 1.19 (0.51–2.77)
Ever had oral sex 
(given/received)
p = 0.008 p = 0.131 p = 0.205 p = 0.410
 No 146/258 (57%) 1 173/261 (66%) 1 142/257 (55%) 1 7/33 (21%) 1
 Yes 36/47 (77%) 2.51 (1.22–
5.15)
37/48 (77%) 1.71 (0.83–
3.52)
30/46 (65%) 1.52 (0.79–
2.92)
39/253 (15%) 0.68 (0.27–1.67)
Ever had transac‑
tional sex
p = 0.748 p = 0.272 p = 0.376 p = 0.2841
 No 170/286 (59%) 1 195/290 (67%) 1 160/285 (56%) 1 42/271 (16%) 1.98 (0.60–6.52)
 Yes 12/19 (63%) 1.17 
(0.45–3.06)
15/19 (79%) 1.83 (0.59–
5.65)
12/18 (67%) 1.56 (0.57–
4.28)
4/15 (27%)
Ever had mutual 
masturbation
p = 0.130 p = 0.162 p = 0.402 p = 0.875
 No 38/73 (52%) 1 46/75 (61%) 1 40/76 (53%) 1 11/71 (16%) 1
 Yes 144/232 (62%) 1.51 
(0.89–2.56)
164/234 (70%) 1.48 (0.86–
2.54)
132/227 (58%) 1.25 (0.74–
2.10)
35/215 (16%) 1.06 (0.51–2.22)
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Table 3 (continued)
Variable Cervical Vulvar Anal Oral
n/N (row, %) P  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 
Crude OR 
(95%CI)
n/N (row, %) p  value1 
Crude OR 
(95%CI)




p = 0.445 p = 0.443 p = 0.938 p = 0.935
 No 88/142 (62%) 1 101/144 (70%) 1 78/138 (57%) 1 21/129 (16%) 1
 Yes 94/163 (58%) 0.84 
(0.53–1.32)
109/165 (66%) 0.83 (0.51–
1.34)
94/165 (57%) 1.02 (0.65–
1.61)
25/157 (16%) 0.97 (0.52–1.84)
Ever drank 
alcohol
p = 0.179 p = 0.012 p = 0.003 p = 0.199
 No 128/223 (57%) 1 144/225 (64%) 1 115/222 (52%) 1 30/209 (14%) 1
 Yes 54/82 (66%) 1.43 
(0.84–2.43)
66/84 (79%) 2.06 (1.15–
3.71)
57/81 (70%) 2.21 (1.28–
3.81)
16/77 (21%) 1.57 (0.80–3.07)
Ever taken any 
illicit drugs
p = 0.011 p = 0.008 p = 0.010 p = 0.813
 No 165/285 (58%) 1 190/287 (66%) 1 154/281 (55%) 1 43/265 (16%) 1
 Yes 17/20 (85%) 4.12 (1.18–
14.38)
20/22 (91%) 5.10 (1.17–
22.29)
18/22 (82%) 3.71 (1.22–
11.24)
3/31 (14%) 0.86 (0.24–3.05)
Ever had an STI p = 0.381 p = 0.209 p = 0.014 p = 0.286
 No 155/264 (59%) 1 178/267 (68%) 1 141/261 (54%) 1 37/245 (15%) 1
 Yes 27/41 (66%) 1.36 
(0.68–2.71)
32/42 (76%) 1.60 (0.75–
3.40)
31/42 (74%) 2.40 (1.16–
4.98)
9/41 (22%) 1.58 (0.70–3.58)
Ever heard of HPV p = 0.039 p = 0.232 p = 0.014 p = 0.890
 No 173/282 (61%) 1 197/286 (69%) 1 165/281 (59%) 1 43/266 (16%) 1
 Yes 9/23 (39%) 0.41 (0.17–
0.97)
13/23 (57%) 0.59 (0.25–
1.39)
7/12 (32%) 0.33 (0.13–
0.83)




NA NA p < 0.001 p < 0.001 p < 0.001
 No 41/123 (33%) 1 30/121 (25%) 1 7/116 (6%) 1
 Yes 166/182 (91%) 20.75 (10.99–
39.17)
138/177 (78%) 10.73 
(6.23–18.50)




p < 0.001 NA NA p < 0.001 p = 0.016
 No 16/98 (16%) 1 15/93 (16%) 1 8/91 (9%) 1
 Yes 166/207 (80%) 20.75 (10.99–
39.17)
156/209 (75%) 15.31 
(8.11–28.86)




p < 0.001 p < 0.001 NA NA p < 0.001
 No 39/130 (30%) 1 53/131 (40%) 1 10/122 (8%) 1
 Yes 138/168 (82%) 10.73 
(6.23–18.50)
156/171 (91%) 15.31 
(8.12–28.86)




p < 0.001 p = 0.016 p < 0.001 NA NA
 No 127/236 (54%) 1 156/239 (65%) 1 122/234 (52%) 1
 Yes 38/45 (84%) 4.66 (2.00–
10.86)
38/46 (83%) 2.53 (1.13–
5.67)
36/46 (78%) 3.30 (1.57–
6.97)
Bold indicates p <0.05 or 95% level of statistical significance
1 p‑values were obtained from Wald tests; 2Hausa/Fulani, Igbo and other minorities; 3Student, apprentice and no job; 4Naira‑ currency of Nigeria; USD –United States 
Dollar; 5Living alone; 6 N = 299 ‑six participants did not provide information on age at first vaginal sex; 7 N = 269—36 participants did not provide information to 
calculate the age difference between first vaginal sex partner and participant; NA not applicable
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Table 4 The adjusted analysis of factors associated with cervical, vulvar, anal and oral human papillomavirus infection among sexually 
active women from the general population in two communities in Ibadan, Nigeria
Variable Cervical Vulvar Anal Oral
p  value1 adjusted OR 
(95%CI)8
p  value1 adjusted OR 
(95%CI)8
p  value1 adjusted OR 
(95%CI)8
p  value1 adjusted OR 
(95%CI)8
Socio-demographic factors
Study site p = 0.576 p = 0.373 p = 0.075 p = 0.004
 Mokola 1 1 1 1
 Moniya/Sasa 0.82 (0.51–1.31) 1.27 (0.75–2.13) 0.63 (0.38–1.05) 0.38 (0.19–0.74)
Age group, years p = 0.018 p = 0.509 p = 0.521 p = 0.693
 18–24 1 1 1 1
 25–34 0.81 (0.46–1.41) 0.89 (0.49–1.63) 0.96 (0.54–1.72) 0.80 (0.38–1.68)
 35–45 0.44 (0.25–0.78) 0.67 (0.34–1.33) 0.70 (0.37–1.35) 0.72 (0.32–1.61)
Ethnicity p = 0.258 p = 0.589 p = 0.920 p = 0.316
 Yoruba 1 1 1 1
  Others2 1.43 (0.77–2.65) 1.22 (0.63–2.38) 0.97 (0.51–1.83) 0.67 (0.30–1.49)
Religion p = 0.648 p = 0.544 p = 0.945 p = 0.767
 Christianity/traditional 1 1 1 1
 Islam 0.89 (0.55–1.46) 0.80 (0.47–1.36) 0.98 (0.59–1.65) 1.11 (0.56–2.17)
Highest education level p = 0.168 p = 0.580 p = 0.556 p = 0.904
 None/primary 1 1 1 1
 Secondary 1.48 (0.81–2.72) 1.05 (0.54–2.02) 1.32 (0.71–2.46) 1.15 (0.48–2.77)
 Tertiary 0.90 (0.45–1.83) 0.71 (0.32–1.57) 1.02 (0.48–2.15) 0.99 (0.35–2.78)
Quranic education p = 0.659 p = 0.897 p = 0.857 p = 0.968
 No 1 1 1 1
 Yes 0.89 (0.55–1.46) 0.94 (0.55–1.59) 1.05 (0.63–1.73) 1.01 (0.52–1.98)
Occupation p = 0.551 p = 0.878 p = 0.520 p = 0.984
 No current paid  job3 1 1 1 1
 Unskilled worker 0.75 (0.25–2.30) 0.71 (0.14–3.55) 1.22 (0.26–5.70) 1.14 (0.26–4.99)
 Semi‑skilled worker 1.11 (0.58–2.15) 0.86 (0.24–3.15) 1.11 (0.33–3.76) 1.09 (0.46–2.55)
 Skilled worker 0.61 (0.21–1.78) 0.66 (0.13–3.24) 0.53 (0.12–2.40) 0.83 (0.15–4.51)
Income per  month4 p = 0.175 p = 0.057 p = 0.084 p = 0.700
 No income 1 1 1 1
 1–10,000 N (1–28USD) 1.26 (0.57–2.79) 0.99 (0.43–2.30) 0.75 (0.33–1.69) 0.83 (0.29–2.36)
 10,001–20,000 N (> 28–56USD) 1.11 (0.48–2.55) 1.43 (0.57–3.57) 2.33 (0.85–6.42) 1.17 (0.40–3.41)
  > 20,000 N (> 56USD) 1.62 (0.66–3.99) 2.62 (0.96–7.13) 0.79 (0.21–2.94) 0.69 (0.21–2.31)
Current marital status p = 0.334 p = 0.027 p = 0.073 p = 0.497
 Single 1 1 1 1
 Married 0.79 (0.43–1.46) 0.49 (0.25–0.99) 0.47 (0.24–0.91) 1.11 (0.50–2.45)
 Divorced/widowed/separated5 1.67 (0.48–5.73) 1.64 (0.38–7.00 0.44 (0.13–1.48) 2.42 (0.60–9.76)
Behavioural factors Adjusted OR (95%CI)9 Adjusted OR (95%CI)9 Adjusted OR (95%CI)9 Adjusted OR (95%CI)9
Age at first vaginal  sex6, years p = 0.700 p = 0.276 p = 0.252 p = 0.202
  ≤ 15 1 1 1 1
 16–17 0.81 (0.29–2.23) 0.44 (0.12–1.58) 0.41 (0.13–1.33) 3.19 (0.78–13.04)
  ≥ 18 1.11 (0.49–2.51) 0.87 (0.29–2.56) 0.75 (0.29–1.99) 1.76 (0.50–6.22)
Age difference between first vaginal 
sex partner and participant,  years7
p = 0.133 p = 0.026 p = 0.050 p = 0.570
  ≤ 5 1 1 1 1
  ≥ 6 0.78 (0.46–1.31) 0.51 (0.29–0.90) 0.58 (0.34–1.00) 0.82 (0.42–1.61)
Number of vaginal sex p = 0.002 p < 0.001 p < 0.001 p = 0.404
 Partners (mean (SD)) 1.54 (1.16–2.04) 2.03 (1.38–3.01) 1.92 (1.35–2.71) 1.09 (0.89–1.33)
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Table 4 (continued)
Behavioural factors Adjusted OR (95%CI)9 Adjusted OR (95%CI)9 Adjusted OR (95%CI)9 Adjusted OR (95%CI)9
Ever cleansed inside vagina p = 0.409 p = 0.072 p = 0.573 p = 0.310
 No 1 1 1 1
 Yes 1.39 (0.63–3.07) 2.61 (0.91–8.77) 1.32 (0.50–3.48) 1.50 (0.70–3.22)
Condom use at last vaginal sex p = 0.923 p = 0.701 p = 0.967 p = 0.909
 No 1 1 1 1
 Yes 0.97 (0.50–1.86) 2.76 (0.97–7.88) 1.32 (0.50–3.48) 1.05 (0.44–2.50)
Ever had oral sex (given/received) p = 0.354 p = 0.802 p = 0.850 p = 0.977
 No 1 1 1 1
 Yes 1.46 (0.65–3.27) 1.12 (0.45–2.81) 0.92 (0.41–2.08) 1.01 (0.40–2.60)
Ever had transactional sex p = 0.321 p = 0.276 p = 0.145 p = 0.266
 No 1 1 1 1
 Yes 0.56 (0.18–1.74) 0.44 (0.10–1.87) 0.37 (0.10–1.40) 2.04 (0.59–7.13)
Ever had mutual masturbation p = 0.133 p = 0.204 p = 0.959 p = 0.508
 No 1 1 1 0.76 (0.34–1.69)
 Yes 1.57 (0.87–2.82) 1.55 (0.79–3.02) 1.02 (0.54–1.93)
Female genital mutilation p = 0.516 p = 0.758 p = 0.584 p = 0.696
 No 1 1 1 1
 Yes 0.80 (0.48–1.33) 1.09 (0.62–1.94) 1.17 (0.67–2.02) 1.14 (0.59–2.19)
Ever drank alcohol p = 0.571 p = 0.864 p = 0.696 p = 0.710
 No 1 1 1 1
 Yes 0.85 (0.52–1.39) 1.07 (0.52–2.19) 1.15 (0.58–2.26) 1.15 (0.56–2.35)
Ever taken any illicit drugs p = 0.105 p = 0.080 p = 0.168 p = 0.437
 No 1 1 1 1
 Yes 3.23 (0.67–15.49) 4.95 (0.58–41.88) 2.63 (0.61–11.33) 0.61 (0.17–2.23)
Ever had an STI p = 0.895 p = 0.558 p = 0.303 p = 0.511
 No 1 1 1 1
 Yes 1.05 (0.50–2.20) 1.29 (0.54–3.07) 1.54 (0.67–3.50) 1.33 (0.57–3.09)
Ever heard of HPV p = 0.091 p = 0.781 p = 0.077 p = 0.887
 No 1 1 1 1
 Yes 0.40 (0.14–1.18) 0.85 (0.25–2.76) 0.35 (0.11–1.17) 1.10 (0.30–4.04)
Biological factors Adjusted OR (95%CI)10 Adjusted OR (95%CI)10 Adjusted OR (95%CI)10 Adjusted OR (95%CI)10
Cervical HPV infection NA p < 0.001 p < 0.001 p = 0.003
 No 1 1 1
 Yes 20.75 (10.99–39.17 4.10 (1.85–9.11) 4.81 (1.58–14.62)
Vulvar HPV infection p < 0.001 NA p < 0.001 p = 0.371
 No 1 1 1
 Yes 12.85 (5.70–28.99) 5.85 (2.35–14.59) 0.57 (0.17–1.95)
Anal HPV infection p < 0.001 p < 0.001 NA p = 0.136
 No 1 1 1
 Yes 3.48 (1.74–6.96) 15.31 (8.12–28.86) 2.02 (0.78–5.25)
Oral HPV infection p < 0.004 p = 0.016 p = 0.119 NA
 No 1 1 1
 Yes 4.37 (1.50–12.71) 2.53 (1.13–5.67) 2.13 (0.80–5.64)
Bold indicates p <0.05 or 95% level of statistical significance
1 p values were obtained from Likelihood Ratio tests; 2Hausa/Fulani, Igbo and other minorities;; 3Student, apprentice and no job; 4 N—Naira‑currency of Nigeria; 
USD—United States Dollar; 5Living alone; 6 N = 299‑six participants did not provide information on age at first vaginal sex; 7 N = 269—36 participants did not provide 
information to calculate the age difference between first vaginal sex partner and participant; 8Level 1 factors were adjusted for age and study site and other level 1 
factors that were significant at p value < 0.10; 9Level 2 factors were adjusted for age and study site (core variables from Level 1), other factors significant at level 1, and 
other level 2 factors that were significant at p value < 0.10; 10Level 3 factors were adjusted for (core variables from Level 1), other level 1 factors, level 2 factors that 
were significant at p value < 0.10, and various biological factors, such as the detection of HPV genotype in the cervical, vulvar, anal and oral cavities of the participant; 
NA not applicable
Page 16 of 20Morhason‑Bello et al. Infect Agents Cancer           (2021) 16:59 
cervix, vulvar, anal and oral cavities. Fifteen of these 
women had concordant HR-HPV genotypes (Table  5; 
Additional file  1: Table  S1). Among women that con-
cordant HR-HPV in the four anatomical sites, two each 
had HPV-16, 18, 39, 51, 58 and 59 genotypes. Out of 16 
participants that had concordance of LR-HPV genotypes 
in the four anatomic sites, HPV-42 was the most preva-
lent type detected in five women followed by HPVs-6, 40 
and 82 in two women each. HPV 45 in 12 women, HPV-
39 in 11 women, HPV-59 in 10 women and HPV-16 in 
9 women were detected in any of their three anatomical 
sites. HPV-42 in 20 women, HPV-6 and 54 in 13 women 
and HPV-66 in 10 women were LR group detected in 
three anatomical sites. Concordance of any HR-HPV 
genotypes was highest in cervical and vulvar samples 
(116/309; 37.5%), followed between anal and vulvar sam-
ples (104/310; 33.5%) and the cervical and anal samples 
(92/310; 29.7%) (Table  5). Concordance of any LR-HPV 
genotype between two anatomical sites samples also fol-
lowed similar pattern with the highest in cervical and 
vulvar samples (123/305; 40.3%).
Discussion
This is the first report on the prevalence of concurrent 
HPV infections in cervix, vulva and oral and anal cavi-
ties among sexually active women living in peri-urban 
and urban settings in West Africa. Generally, the preva-
lence of HPV was highest in the vulvar, followed by the 
cervical or anal and oral sites. We observed almost dou-
ble the prevalence of any HPV, HR and LR-HPV cervical 
infections in this study compared with previous studies 
in Nigeria. However, the pattern of age-specific preva-
lences were similar [9, 11, 14]. For example, a community 
survey two decades ago (1999–2000) among 932 women 
aged 15  years and above in Idikan, Ibadan, southwest 
Nigeria, found prevalences of 26.3% for any HPV infec-
tion, 18.3% for any HR-HPV and 6.5% for any LR cervical 
HPV infections among the study population [9]. In 2012, 
another study conducted in Abuja, central Nigeria among 
278 women who were 18  years and above, reported a 
prevalence of any HPV genotype of 37.0% and any HR 
genotype of 22.0% in their cervical samples [11]. The rel-
atively high prevalence of cervical HPV infection in the 
present study may possibly be due to differences in the 
age group cut-off, type of assay methods used to detect 
HPV and sexual behaviours across different generations, 
which appear to be increasing with time, particularly in 
young population of women. Watson-Jones et al. (2013), 
also established a very high prevalence (74.0%) of HPV 
infection among 334 sexually active female adolescents 
and young adults (10–25  years) in Mwanza, Tanzania 
[17]. Worldwide, the prevalence of cervical HPV in the 
general population is known to be high during the sexual 
debut and early adulthood stage and declines with age 
reaching a plateau by 40 years [2]. However, in some Afri-
can countries, and Asia and Oceanian populations, there 
is typically a second peak of prevalence of cervical HPV 
infection in women aged 50 years and above [2]. The pre-
sent study did not observe the second peak for the reason 
that it did not include females above 45 years of age and 
it may also be a reflection of what is observed in other 
studies. The relatively high prevalence of any HR-HPV in 
this study compared to 5% observed in Europe in this age 
group (i.e. within the age group recommended by WHO 
for HPV screening) may suggest a higher burden of per-
sistence HPV in Nigeria [18].
The prevalence of anal HPV infection was lower than 
the reported prevalence of 67.1% among 173 women (18–
69 years) in Brazil [19]. There is a paucity of data on the 
prevalence of anal HPV infections among women in the 
general population in SSA. The few studies that reported 
anal HPV infection were mostly in key affected popula-
tions [20, 21]. A Zimbabwean study (2014–2015) among 
88 HIV positive adult women (≥ 18  years) reported the 
prevalence of any anal HPV infection of 60.3% [20]. In 
South Africa, one study compared the detection of anal 
HPV by GeneXpert and Hybrid capture 2 methods in 
a population of 200 HIV positive women 18  years and 
above. This study ascertained anal HPV detection of 
40.8% and 41.8% with GeneXpert and Hybrid capture 2 
techniques, respectively [21].
The data on the prevalence of vulvar HPV infec-
tion among women in the general population are lim-
ited compared to other anogenital sites. Studies that 
reported on vulvar HPV infections were typically 
conducted among women that had vulvar lesions and 
were not representative of general population preva-
lence estimates of vulvar HPV infections [22, 23]. Of 
the three studies that presented data on the prevalence 
of any vulvar HPV infection two (from China and UK) 
were population studies, while a study from the US was 
a review of medical records [24–26]. The Chinese study 
reported relatively low vulvar HPV prevalence of 13.3% 
for any HPV and 12.8% for any HR-HPV in vulvar sam-
ples of 2,327 adult women (18–55%) in the commu-
nity [24]. A study in the UK among 3829 women aged 
25  years and below reported that 34.6% had any HR 
vulvar HPV infection [26]. The reported prevalences 
in these two studies were lower than reported in the 
present study at 51.1%, although the UK study did not 
report the prevalence of LR-HPV types and the Chi-
nese study included older women. The high prevalence 
of vulvar HPV infection relative to other genital sites 
had been associated with the hypothesis of viral shed-
ding from infection of contiguous anatomical struc-
tures such as the cervix and anus. The low incidence 
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Table 5 Proportion of HPV genotype specific concordance samples across the four anatomical sites of the cervix, vulvar, anal and oral 






Women with the 
same HPV 
genotype in all 
the 4 sites (%)
Women with the 
same HPV 
genotype in any 3 
sites (%)
Women with the 
same HPV 
genotype in any 
2 sites (%)
Women with 
HPV genotype in 
1 site only (%)
Women with 
any HPV 16
Yes (n=24) 2/24 (8%) 9/24 (38%) 2/24 (8%) 11 (46%)
No (n=26) – – – –
Women with 
any HPV 18
Yes (n=25) 2/25 (8%) 4 /25(16%) 5 /25(20%) 14 /25(56%) 
No (n=19) – – – –
Women with 
any HPV 31 
Yes (n=19) 0 5/19 (26%) 5/19 (26%) 9/19 (48%)
No (n=15) – – – –
Women with 
any HPV 33
Yes (n=9) 0 3/9 (33%) 2/9 (22%) 4/9 (45%)
No (n=8) – – – – 
Women with 
any HPV 35
Yes (n=36) 1/36 (3%) 14/36 (39%) 9/36 (25%) 12/36 (33%) 
No (n=40) – – – – 
Women with 
any HPV 39 
Yes (n=30) 2/30 (7%) 11/30 (37%) 7/30 (23%) 10/30 (33%) 
No (n=36) – – – – 
Women with 
any HPV 45 
Yes (n=34) 0 12/34 (35%) 9/34 (27%) 13/34 (38%) 
No (n=33) – – – –
Women with 
any HPV 51 
Yes (n=30) 2/30 (7%) 6/30 (20%) 5/30 (17%) 17/30 (56%) 
No (n=23) – – – –
Women with 
any HPV 52
Yes (n=40) 0 9/40 (23%) 10/40 (25%) 21/40 (52%)
No (n=28) – – – – 
Women with 
any HPV 56
Yes (n=23) 1/23 (4%) 6/23 (26%) 5/23 (22%) 11/23 (48%) 
No (n=20) – – – – 
Women with
any HPV 58
Yes (n=35) 2/35 (6%) 5/35 (14%) 7/35 (20%) 21/35 (60%) 
No (n=23) – – – –
Women with 
any HPV 59
Yes (n=25) 2/25 (8%) 10/25 (40%) 4/25 (16%) 9/25 (36%) 
No (n=30 – – – –
Women with
any HPV 68
Yes (n=28) 1/28 (4%) 7/28 (25%) 8/28 (28%) 12/28 (43%) 
No (n=25) – – – –
Women with 
any HPV 6 
Yes (n=43) 2/43 (5%) 13/43 (30%) 8/43 (19%) 20/43 (46%) 
No (n=40) – – – – 
Women with 
any HPV 11
Yes (n=3) 0 0 2/3 (67%) 1/3 (33%) 
No (n=2) – – – – 
Women with
any HPV 26 
Yes (n=6) 0 2/6 (33%) 1/6 (17%) 3/6 (50%)
No (n=5) – – – – 
Women with 
any HPV 40
Yes (n=28) 2/28 (7%) 9/28 (32%) 5/28 (18%) 12/28 (43%) 
No (n=29) – – – –
Women with
any HPV 42 
Yes (n=63) 5/63 (8%) 20/63 (32%) 6/63(9%) 32/63 (51%) 
No (n=61) – – – 
Women with Yes (n=19) 0 9/19 (48%) 5/19 (26%) 5/19 (26%) 
any HPV 43 No (n=23) – – – –
Women with 
any HPV 44
Yes (n=18) 1/18 (6%) 8 /18(44%) 4/18 (22%) 5/18 (28%) 
No (n=23) – – – – 
Women with 
any HPV 53 
Yes (n=39) 0 9/39 (23%) 8/39 (21%) 22/39 (56%) 
N (n=26) – – – –
Women with
any HPV 54 
Yes (n=37) 0 13/37 (35%) 14/37 (38%) 10/37 (27%)
No (n=40) – – – –
Women with 
any HPV 61
Yes (n=15) 0 0 7/15 (47%) 8/15 (53%)
No (n=7) – – – –
Women with 
any HPV 66
Yes (n=37) 1/37 (3%) 10/37 (27%) 9/37 (24%) 17/37 (46%)
No (n=32) – – – –
Women with 
any HPV 69 
Yes (n=5) 0 1/5 (20%) 0 4/5 (80%) 
No (n=2) – – – – 
Women with
any HPV 70 
Yes (n=11) 0 5/11 (45%) 1/11 (9%) 5/11 (45%) 
No (n=11) – – –
Women with
any HPV 73 
Yes (n=14) 0 8/14 (57%) 2/14 (14%) 4/14 (29%)
No (n=18) – – – – 
Women with 
any HPV 82 
Yes (n=18) 2/18 (11%) 5/18 (28%) 4/18 (22%) 7/18 (39%) 
No (n=20) – – – – 
1-Orange colour used to highlight HR-HPV genotypes; 2-Sky-blue colour used to indicate LR-HPV genotypes; 
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of vulvar cancer relative to cervical cancer globally and 
in Nigeria, suggest that the observed high prevalence 
of vulvar HPV in this population does not translate to 
high burden of vulvar cancer. In addition, vulva has 
lower susceptibility to carcinogenesis when compared 
to the cervical tissue.
The prevalence of any or HR oral HPV infections was 
lower than for the other three anatomical sites. Oral HPV 
infections including HR genotypes were higher in this 
study than some previous studies [27, 28]. Specifically, 
the prevalence of any HPV and HR-HPV infections were 
three times higher than the global averages presented in 
two different systematic reviews that involved 26 stud-
ies among females that were 18 years and above in 2018 
(any HPV-5.5%; HR-HPV-2.3%) and 21 studies in 2019 
(any HPV-3.8%; HR-HPV-2.6%) among healthy ado-
lescents and adult women [27, 28]. However, in 2016, a 
study in Austria reported a prevalence of 18.1% on oral 
HPV infection among 310 adolescent and adult females 
(18–20  years), which was similar to the findings in this 
study [29].
HPV-35 was the most common HR genotypes in the 
cervix and vulva, HPV-52 in the anal cavity and HPV-51 
in the oral cavity. HPV-42 was the most common LR gen-
otypes in all anatomic sites in this study. Previous studies 
in Nigeria had also reported HPV35 and 42 as the most 
prevalent for cervical HPV infection [9, 11]. Studies in 
women in South Africa, Zimbabwe and Tanzania found 
HPV 16 as the most prevalent HR-HPV in the cervix, 
oral and anal cavities [20, 21, 30–32]. The prevalence of 
HPV-16 and -18, which are associated with 70% of HPV-
associated cancers was relatively low in this study [33]. 
The detection of HPV-16 and -18 could imply a higher 
risk of detection of similar genotypes in other genital 
and oral sites. Although, HPV-16 and -18 are the two 
most common genotypes associated with cervical can-
cer globally, the burden of other HR-HPV types is cru-
cial in deciding which HPV vaccine should be adopted, 
besides other factors like the cost and availability of the 
vaccine. It is equally important that future design of HPV 
vaccines should consider inclusion of HPV-35 because of 
the increasing report of this genotype in invasive cervical 
cancer samples particularly in people of African origin 
[18].
All the risk factors associated with cervical, vulvar, anal 
and oral HPV infection had been previously reported 
in other studies [24, 26, 27, 34–36]. A number of other 
risk factors that were previously reported for HPV infec-
tions in specific anatomical sites that were not found to 
be associated or not considered in the analyses in this 
study [37, 38]. A meta-analyses of risk factors associated 
with oral HPV infection in 2018 reported mixed findings 
on the association between oral sex and risk of oral HPV 
infection [27]. Some studies documented a strong asso-
ciation between oral sex and oral HPV, other studies did 
not [27].
Concomitant cervical HPV infection appeared as a 
constant risk factor for oral, vulvar and anal HPV infec-
tion in this study. In 2019, a meta-analysis of pooled data 
involving 13,427 women with paired cervical and anal 
samples showed that cervical and anal HPV infections 
were highly correlated, particularly in HR-HPV genotype 
specific infections [39]. Concomitant HPV infection in 
oro-genital sites may be due to sexual behaviour, autoin-
oculation or viral shedding with deposition in secretions 
at another site subsequently being detected as infection 
in that site. The latter may be particularly substantial 
regarding the concurrent detection of vulvar and cervical 
HPV infections.
There are potential limitations in this study. We were 
unable to report on the prevalence of adults older than 
45 years which is the period when the second peak prev-
alence of HPV infections is sometimes reported. The 
exclusion of sexually naïve females could also have con-
tributed to the high prevalence of HPV. The cross-sec-
tional design of the study did not allow for investigation 
of risk factors for HPV persistence and the clearance. It 
was not possible to test for association between different 
types of oral sex (given or received) and oral HPV infec-
tion. The risk of oral HPV has been reported to be higher 
in individuals that received oral sex compared to those 
that give oral sex [27, 40]. Anal sex was also not consid-
ered in the risk factor analysis for anal HPV infection. It 
was also impossible to perform risk factor analyses of, 
and concordance for HPV infections in different anatom-
ical sites among women that were HIV positive due to 
small number of observations. Despite these limitations, 
our study provided vital information on the burden of 
HPV infections in sexually active women that are within 
the recommended age limit set by WHO for HPV test-
ing, our data provide a fair estimate of women with HPV 
infections in a Nigerian community.
In conclusion, this study provides a robust estimate of 
cervical, vulvar, anal and oral HPV prevalence among 
sexually active women in the general population within 
the age range for HPV screening in Nigeria and demon-
strates how prevalent HPV infection is in these women. 
The risk factors for specific HPV infection of different 
anatomical sites were similar to findings in previous stud-
ies. Although HPV infection is transient, the relatively 
high HPV infection in all anatomical sites relative to pre-
vious studies may possibly be due to the changing sexual 
behaviour and increasing sexual risk practices in the 
general population, in addition to the study design and 
the characteristics of study population. The detection of 
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HPV-35 and -51 as part of the most prevalent HR-HPV 
types in the genital (cervix and vulva), anal cavity and 
oral cavity, respectively, may suggest the need to consider 
the coverage of these genotypes in future HPV vaccine 
design, especially so for HPV-35, that is being reported 
commonly in invasive genital cancers [41].
We advocate adequately powered population level 
longitudinal studies that can investigate the persistence 
of HR-HPV infections in different anatomic sites to bet-
ter understand the epidemiology of HPV and associated 
malignancies in SSA. This information will help policy 
makers to make evidence based informed decisions on 
prevention and management of HPV infections and asso-
ciated cancers in Nigeria and other countries with similar 
demographic profiles in SSA.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s13027‑ 021‑ 00398‑9.
Additional file 1: Fig S1. Conceptual framework for the risk factor 
analysis of any HPV infection among females in the two communities 
in Ibadan, Nigeria. Fig S2. Prevalence with 95% confidence intervals of 
specific HPV genotypes in the four anatomic sites. Table S1. Pattern of 
HPV concordance by means of anatomical sites among females in Ibadan, 
Nigeria (n=310).
Acknowledgements
IMB received grant support from the University of Ibadan, Ibadan, Nigeria 
for his PhD programme at London School of Hygiene and Tropical Medicine, 
London. We appreciate the technical support of the staff of National Popula‑
tion Commission, Oyo State, the office of the Surveyor General in Oyo State, 
Dr M. Olatunji the Executive Director of Oyo State Primary Healthcare Board 
(formerly Medical Officer of Health, Akinyele LGA); Dr A. Famakin (Medical 
Officer of Health, Ibadan North LGA and Dr Bunmi Ayinde (Deputy Director, 
Ministry of Health, Oyo State).
Authors’ contributions
Conceptualization: IMB, SCF and DWJ; Data collection and Supervision: IMB, 
SCF, DWJ, KB, IFA, RA; SD; Laboratory Analysis: MP, SD; Data Analysis and Inter‑
pretation of results: IMB, SCF, DWJ, KA; Writing of first draft: IMB; Writing and 
Approval: All authors. All authors read and approved the final manuscript.
Funding
This study was supported by the Management of University of Ibadan, Ibadan, 
Nigeria under Staff Development Program Grant. The Funder did not partici‑
pate in the design and interpretation of results of this study.
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
Ethical approvals were obtained from the ethical committees of the London 
School of Hygiene and Tropical Medicine, London (LSHTM 9736‑3); the Univer‑
sity of Ibadan/the University College Hospital, Ibadan (UI/EC/16/005); and the 
Oyo State Government (AD13/479/712) in Nigeria.
Consent for publication
Participants gave a written consent for participation and for their data to be 
published in a scientific journal.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Obstetrics and Gynaecology Department, Faculty of Clinical Sciences, College 
of Medicine/University College Hospital, University of Ibadan, Ibadan, Oyo 
State, Nigeria. 2 Institute of Advance Medical Research and Training, College 
of Medicine, University of Ibadan, Ibadan, Nigeria. 3 Department of Infec‑
tious Disease Epidemiology, Faculty of Epidemiology and Population Health, 
London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 
7HT, UK. 4 Infection and Cancer Laboratory, Cancer Epidemiology Research 
Program, ICO, Bellvitge Biomedical Research Institute (IDIBELL), Centro de 
Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 
L’Hospitalet de Llobregat, Gran Via de l’Hospitalet, 199‑203, 08908 Barcelona, 
Spain. 5 Department of Microbiology, Faculty of Basic Medical Sciences, Col‑
lege of Medicine, University of Ibadan, Ibadan, Nigeria. 6 Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center 
Drive, Rockville, MD, USA. 7 Mwanza Intervention Trials Unit, National Institute 
for Medical Research, Mwanza, Tanzania. 8 Clinical Research Department, Fac‑
ulty of Infectious and Tropical Diseases, London School of Hygiene and Tropi‑
cal Medicine, Keppel St, London WC1E 7HT, UK. 
Received: 5 July 2021   Accepted: 24 August 2021
References
 1. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. 
Curr Probl Dermatol. 2014;45:75–91.
 2. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de 
Sanjosé S: ICO/IARC Information Centre on HPV and Cancer (HPV Infor‑
mation Centre). Human papillomavirus and related diseases in the world. 
Summary Report 22 January 2019; 2019. Accessed 13 March 2019.
 3. de Sanjose S, Brotons M, Pavon MA. The natural history of human papil‑
lomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.
 4. Prigge ES, von Knebel Doeberitz M, Reuschenbach M. Clinical relevance 
and implications of HPV‑induced neoplasia in different anatomical loca‑
tions. Mutat Res Rev Mutat Res. 2017;772:51–66. https:// doi. org/ 10. 1016/j. 
mrrev. 2016. 1006. 1005.
 5. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of 
HPV‑related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14–26. 
https:// doi. org/ 10. 1016/j. bpobg yn. 2017. 1008. 1006.
 6. Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infec‑
tion to cancer in the anus, according to sex and HIV status: a systematic 
review and meta‑analysis. Lancet Infect Dis. 2018;18(2):198–206.
 7. Single‑Dose HPV Evaluation Consortium: Review of the current published 
evidence on Single‑Dose HPV vaccination (2nd Edition), 30 June 2019; 
2019. https:// path. azure edge. net/ media/ docum ents/ SDHPV_ White 
paper_ 2019F inal. pdf. Accessed 13 Oct 10.
 8. Jedy‑Agba EE, Dareng EO, Adebamowo SN, Odutola M, Oga EA, Igbinoba 
F, Otu T, Ezeome E, Bray F, Hassan R, et al. The burden of HPV associ‑
ated cancers in two regions in Nigeria 2012–2014. Cancer Epidemiol. 
2016;45:91–7.
 9. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, 
Oladepo O, Smith JS, Arslan A, Munoz N, et al. Prevalence of papillomavi‑
rus infection in women in Ibadan, Nigeria: a population‑based study. Br J 
Cancer. 2004;90(3):638–45.
 10. Ezechi OC, Ostergren PO, Nwaokorie FO, Ujah IA, Odberg Pettersson K. 
The burden, distribution and risk factors for cervical oncogenic human 
papilloma virus infection in HIV positive Nigerian women. Virol J. 
2014;11:5.
 11. Akarolo‑Anthony SN, Famooto AO, Dareng EO, Olaniyan OB, Offiong 
R, Wheeler CM, Adebamowo CA. Age‑specific prevalence of human 
papilloma virus infection among Nigerian women. BMC Public Health. 
2014;14:656.
Page 20 of 20Morhason‑Bello et al. Infect Agents Cancer           (2021) 16:59 
 12. Musa J, Taiwo B, Achenbach C, Olugbenga S, Berzins B, Sagay AS, Idoko 
JA, Kanki PJ, Murphy RL. High‑risk human papillomavirus among HIV‑
infected women with normal cervical cytology: a pilot study in Jos, 
Nigeria. Arch Gynecol Obstet. 2013;288(6):1365–70.
 13. Nejo YT, Olaleye DO, Odaibo GN. Prevalence and risk factors for genital 
human papillomavirus infections among women in Southwest Nigeria. 
Arch Basic Appl Med. 2018;6(1):105–12 (Epub 2018 May 2014).
 14. Okolo C, Franceschi S, Adewole I, Thomas JO, Follen M, Snijders PJ, 
Meijer CJ, Clifford GM. Human papillomavirus infection in women with 
and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer. 
2010;5(1):24.
 15. National Population Commission: Nigeria Data Porta; 2006. Available from 
http:// niger ia. opend atafo rafri ca. org/ xsppl pb/ niger ia‑ census. Accessed 23 
Sept 2019.
 16. Federal Ministry of Health: National Guidelines on the Syndromic Man‑
agement of Sexually Transmitted Infections (STIs) and other Reproductive 
Tract Infections (RTIs). FMOH, Abuja. 2016.
 17. Watson‑Jones D, Baisley K, Brown J, Kavishe B, Andreasen A, Changalucha 
J, Mayaud P, Kapiga S, Gumodoka B, Hayes RJ, et al. High prevalence and 
incidence of human papillomavirus in a cohort of healthy young African 
female subjects. Sex Transmit Infect. 2013;89(5):358–65.
 18. Campos NG, Demarco M, Bruni L, Desai KT, Gage JC, Adebamowo SN, de 
Sanjose S, Kim JJ, Schiffman M. A proposed new generation of evidence‑
based microsimulation models to inform global control of cervical 
cancer. Prev Med. 2021;144:106438.
 19. Tosato Boldrini NA, Bondi Volpini LP, de Freitas LB, Musso C. Mercon de 
Vargas PR, Spano LC, Miranda AE: Anal HPV infection and correlates in 
HIV‑infected patients attending a Sexually Transmitted Infection clinic in 
Brazil. PLoS One. 2018;13(7):e0199058.
 20. Chinyowa S, Palefsky JM, Chirenje ZM, Makunike‑Mutasa R, Munjoma M, 
Muguti GI. Anal human papillomavirus infection in HIV‑positive men and 
women at two opportunistic infections clinics in Harare, Zimbabwe. BMC 
Public Health. 2018;18(1):1260.
 21. Mbulawa ZZA, Wilkin T, Goeieman BJ, Jong E, Michelow P, Swarts A, Smith 
JS, Kegorilwe P, Firnhaber CS, Williamson AL. Prevalence of anal human 
papillomavirus (HPV) and performance of cepheid xpert and hybrid 
capture 2 (hc2) HPV assays in South African HIV‑infected women. Am J 
Clin Pathol. 2017;148(2):148–53.
 22. Ngamkham J, Boonmark K, Phansri T. Detection and type‑distribution 
of human papillomavirus in vulva and vaginal abnormal cytology 
lesions and cancer tissues from Thai women. Asian Pac J Cancer Prev. 
2016;17(3):1129–34.
 23. Faber MT, Sand FL, Albieri V, Norrild B, Kjaer SK, Verdoodt F. Preva‑
lence and type distribution of human papillomavirus in squamous 
cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer. 
2017;141(6):1161–9.
 24. Wei F, Li M, Wu X, Yin K, Lan J, Sheng W, Guo M, Huang S, Wang Y, Li Y, et al. 
The prevalence and concordance of human papillomavirus infection in 
different anogenital sites among men and women in Liuzhou, China: a 
population‑based study. Int J Cancer. 2018;142(6):1244–51.
 25. Sahasrabuddhe VV, Gravitt PE, Dunn ST, Brown D, Allen RA, Eby YJ, Smith 
K, Zuna RE, Zhang RR, Gold MA, et al. Comparison of human papillo‑
mavirus detections in urine, vulvar, and cervical samples from women 
attending a colposcopy clinic. J Clin Microbiol. 2014;52(1):187–92.
 26. Howell‑Jones R, de Silva N, Akpan M, Oakeshott P, Carder C, Coupland 
L, Sillis M, Mallinson H, Ellis V, Frodsham D, et al. Prevalence of human 
papillomavirus (HPV) infections in sexually active adolescents and young 
women in England, prior to widespread HPV immunisation. Vaccine. 
2012;30(26):3867–75.
 27. Mena M, Taberna M, Monfil L, Arbyn M, de Sanjosé S, Bosch FX, Alemany 
L, Bruni L. Might oral human papillomavirus (HPV) infection in healthy 
individuals explain differences in HPV‑attributable fractions in oro‑
pharyngeal cancer? A systematic review and meta‑analysis. J Infect Dis. 
2019;219(10):1574–85.
 28. Tam S, Fu S, Xu L, Krause KJ, Lairson DR, Miao H, Sturgis EM, Dahlstrom KR. 
The epidemiology of oral human papillomavirus infection in healthy pop‑
ulations: a systematic review and meta‑analysis. Oral Oncol. 2018;82:91–9.
 29. Dalla Torre D, Burtscher D, Solder E, Widschwendter A, Rasse M, Puelacher 
W. The impact of sexual behavior on oral HPV infections in young unvac‑
cinated adults. Clin Oral Investig. 2016;20(7):1551–7.
 30. Baisley KJ, Andreasen A, Irani J, Nnko S, Changalucha J, Crucitti T, Francis 
S, Holm Hansen C, Hayes RJ, Buve A, et al. HPV prevalence around the 
time of sexual debut in adolescent girls in Tanzania. Sex Transm Infect. 
2019;20(054012):2019–054012.
 31. Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL. 
Cervical and oral human papillomavirus types in HIV‑1 positive and 
negative women with cervical disease in South Africa. J Med Virol. 
2008;80(6):953–9. https:// doi. org/ 10. 1002/ jmv. 21166.
 32. Vogt SL, Gravitt PE, Martinson NA, Hoffmann J, D’Souza G. Concordant 
oral‑genital HPV infection in South Africa couples: evidence for transmis‑
sion. Front Oncol. 2013;3:303.
 33. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of 
cancer attributable to HPV by site, country and HPV type. Int J Cancer. 
2017;141(4):664–70.
 34. Stier EA, Sebring MC, Mendez AE, Ba FS, Trimble DD, Chiao EY. Prevalence 
of anal human papillomavirus infection and anal HPV‑related disorders in 
women: a systematic review. Am J Obstet Gynecol. 2015;213(3):278–309.
 35. Yuan XW, Li YJ, Qiu Q, Luo ZY, Zhao XF. Prevalence and genotype distribu‑
tion of human papillomavirus among 9945 women from the Nanhai area 
of Foshan. BMC Infect Dis. 2019;19(1):71.
 36. Thorsteinsson K, Storgaard M, Katzenstein TL, Ladelund S, Ronsholt 
FF, Johansen IS, Pedersen G, Gaardsting A, Nielsen LN, Bonde J, et al. 
Prevalence of cervical, oral, and anal human papillomavirus infection in 
women living with HIV in Denmark—the SHADE cohort study. J Clin Virol. 
2018;105:64–71.
 37. Rajendra Santosh AB, Christian NA, Jones T, Thoms‑Rodriguez CA, 
Condappa A, Thompson T, Pinkney J, Barton EN, Lindo J. Molecular 
epidemiology of human papillomavirus genotypes in oral rinses from 
HIV‑positive and HIV‑negative Jamaican patients. J Investig Clin Dent. 
2019;10(1):e12365.
 38. Kiwerska K, Jozefiak A, Markowska J, Kedzia W, Jackowska J, Wierzbicka M. 
Oral‑genital human papillomavirus infection in Polish couples: frequent 
detection of HPV 42. BMC Infect Dis. 2019;19(1):122.
 39. Lin C, Slama J, Gonzalez P, Goodman MT, Xia N, Kreimer AR, Wu T, Hessol 
NA, Shvetsov Y, Ortiz AP, et al. Cervical determinants of anal HPV infection 
and high‑grade anal lesions in women: a collaborative pooled analysis. 
Lancet Infect Dis. 2019;19(8):880–91. https:// doi. org/ 10. 1016/ S1473‑ 
3099(1019) 30164‑ 30161.
 40. Gillison ML, Broutian T, Pickard RKL, Tong Z, Xiao W, Kahle L, Graubard 
BI, Chaturvedi AK. Prevalence of Oral HPV Infection in the United States, 
2009–2010. JAMA. 2012;307(7):693–703.
 41. Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, Snyman L, 
Wiredu E, Molijn A, Quint W, et al. Human papillomavirus prevalence and 
type distribution in invasive cervical cancer in sub‑Saharan Africa. Int J 
Cancer. 2014;134(6):1389–98.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
